Artiva Biotherapeutics, Common Stock Performance
| ARTV Stock | 11.04 0.64 6.15% |
The firm shows a Beta (market volatility) of 0.71, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Artiva Biotherapeutics,'s returns are expected to increase less than the market. However, during the bear market, the loss of holding Artiva Biotherapeutics, is expected to be smaller as well. Artiva Biotherapeutics, right now shows a risk of 6.59%. Please confirm Artiva Biotherapeutics, potential upside, as well as the relationship between the accumulation distribution and price action indicator , to decide if Artiva Biotherapeutics, will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Artiva Biotherapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Artiva Biotherapeutics, is not utilizing all of its potentials. The newest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
Actual Historical Performance (%)
One Day Return (9.69) | Five Day Return (5.41) | Year To Date Return (16.92) | Ten Year Return (16.92) | All Time Return (16.92) |
1 | Disposition of 214692 shares by 5am Partners Vi, Llc of Artiva Biotherapeutics, subject to Rule 16b-3 | 10/18/2024 |
2 | Insider Trading | 10/21/2024 |
3 | Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference | 11/11/2024 |
4 | Artiva Biotherapeutics Given Buy Rating at Needham Company LLC | 11/14/2024 |
| Begin Period Cash Flow | 102.8 M |
Artiva |
Artiva Biotherapeutics, Relative Risk vs. Return Landscape
If you would invest 1,246 in Artiva Biotherapeutics, Common on September 20, 2024 and sell it today you would lose (142.00) from holding Artiva Biotherapeutics, Common or give up 11.4% of portfolio value over 90 days. Artiva Biotherapeutics, Common is currently generating 0.0186% in daily expected returns and assumes 6.5851% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than Artiva, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Artiva Biotherapeutics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Artiva Biotherapeutics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Artiva Biotherapeutics, Common, and traders can use it to determine the average amount a Artiva Biotherapeutics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0028
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ARTV |
Estimated Market Risk
| 6.59 actual daily | 58 58% of assets are less volatile |
Expected Return
| 0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Artiva Biotherapeutics, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Artiva Biotherapeutics, by adding Artiva Biotherapeutics, to a well-diversified portfolio.
Artiva Biotherapeutics, Fundamentals Growth
Artiva Stock prices reflect investors' perceptions of the future prospects and financial health of Artiva Biotherapeutics,, and Artiva Biotherapeutics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Artiva Stock performance.
| Return On Equity | -0.44 | ||||
| Operating Margin | (23.45) % | ||||
| Current Valuation | 136.49 M | ||||
| Shares Outstanding | 24.29 M | ||||
| Price To Book | 1.33 X | ||||
| Price To Sales | 103.10 X | ||||
| Revenue | 33.49 M | ||||
| EBITDA | (28.41 M) | ||||
| Net Income | (28.72 M) | ||||
| Total Debt | 16.91 M | ||||
| Book Value Per Share | 8.28 X | ||||
| Cash Flow From Operations | (47.43 M) | ||||
| Earnings Per Share | (2.48) X | ||||
| Market Capitalization | 268.15 M | ||||
| Total Asset | 105.11 M | ||||
| Retained Earnings | (181.31 M) | ||||
| Working Capital | 67.59 M | ||||
About Artiva Biotherapeutics, Performance
Evaluating Artiva Biotherapeutics,'s performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Artiva Biotherapeutics, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Artiva Biotherapeutics, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.26) | (0.28) | |
| Return On Capital Employed | (0.33) | (0.35) | |
| Return On Assets | (0.26) | (0.28) | |
| Return On Equity | 0.17 | 0.16 |
Things to note about Artiva Biotherapeutics, performance evaluation
Checking the ongoing alerts about Artiva Biotherapeutics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Artiva Biotherapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Artiva Biotherapeutics, had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 33.49 M. Net Loss for the year was (28.72 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Artiva Biotherapeutics, generates negative cash flow from operations | |
| Artiva Biotherapeutics, has a frail financial position based on the latest SEC disclosures | |
| Over 89.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Artiva Biotherapeutics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Artiva Biotherapeutics,'s stock is overvalued or undervalued compared to its peers.
- Examining Artiva Biotherapeutics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Artiva Biotherapeutics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Artiva Biotherapeutics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Artiva Biotherapeutics,'s stock. These opinions can provide insight into Artiva Biotherapeutics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Artiva Stock Analysis
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.